South Korea · Delayed Price · Currency is KRW Ingenia Therapeutics Statistics
Total Valuation
KOSDAQ:950260 has a market cap or net worth of KRW 913.24 billion. The enterprise value is 900.85 billion.
| Market Cap | 913.24B |
| Enterprise Value | 900.85B |
Important Dates
The next estimated earnings date is Thursday, November 19, 2026.
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KOSDAQ:950260 has 49.44 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 49.44M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +24.19% |
| Owned by Insiders (%) | 26.32% |
| Owned by Institutions (%) | 2.86% |
| Float | 15.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 123.09 |
| PB Ratio | 60.07 |
| P/TBV Ratio | 64.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 121.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 0.10.
| Current Ratio | 1.72 |
| Quick Ratio | 1.45 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | -142.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -551.67% |
| Return on Capital Employed (ROCE) | -161.75% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 370.96M |
| Profits Per Employee | -1.12B |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.16B |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 55.85 |
| Average Volume (20 Days) | 4,450,811 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KOSDAQ:950260 had revenue of KRW 7.42 billion and -22.38 billion in losses. Loss per share was -807.42.
| Revenue | 7.42B |
| Gross Profit | 7.42B |
| Operating Income | -25.50B |
| Pretax Income | -24.54B |
| Net Income | -22.38B |
| EBITDA | -24.32B |
| EBIT | -25.50B |
| Loss Per Share | -807.42 |
Balance Sheet
The company has 13.89 billion in cash and 1.50 billion in debt, with a net cash position of 12.39 billion or 250.60 per share.
| Cash & Cash Equivalents | 13.89B |
| Total Debt | 1.50B |
| Net Cash | 12.39B |
| Net Cash Per Share | 250.60 |
| Equity (Book Value) | 15.20B |
| Book Value Per Share | 329.82 |
| Working Capital | 6.91B |
Cash Flow
In the last 12 months, operating cash flow was -17.46 billion and capital expenditures -1.05 billion, giving a free cash flow of -18.50 billion.
| Operating Cash Flow | -17.46B |
| Capital Expenditures | -1.05B |
| Depreciation & Amortization | 1.18B |
| Net Borrowing | -768.07M |
| Free Cash Flow | -18.50B |
| FCF Per Share | -374.21 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -343.75% |
| Pretax Margin | -330.72% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KOSDAQ:950260 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -2.45% |
| FCF Yield | -2.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KOSDAQ:950260 has an Altman Z-Score of -4.53 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.53 |
| Piotroski F-Score | 1 |